Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | POLB | P06746 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.58 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.58 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.58 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.58 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14461305 | 0.85 | HDAC1 (0.72) | NOTUMRAB9APOLBLMNATSHR | |
| SCHEMBL4938762 | 0.84 | RAB9A (0.68) | NOTUMRAB9APOLBLMNATSHR | |
| SCHEMBL4929814 | 0.81 | HDAC1 (0.71) | NOTUMRAB9APOLBLMNATSHR | |
| SCHEMBL16428961 | 0.80 | RAB9A (0.57) | NOTUMRAB9APOLBLMNATSHR | |
| SCHEMBL5404742 | 0.80 | MEN1 (0.66) | RAB9APOLBLMNATSHRHDAC1 | |
| SCHEMBL9670295 | 0.79 | RAB9A (0.62) | NOTUMRAB9APOLBLMNATSHR | |
| SCHEMBL5158122 | 0.79 | MGAM (0.54) | NOTUMRAB9APOLBLMNATSHR | |
| SCHEMBL20509078 | 0.79 | HDAC1 (0.76) | NOTUMRAB9APOLBLMNATSHR | |
| Propionic Acid SCHEMBL9670302 | 0.79 | HDAC1 (0.64) | NOTUMRAB9APOLBLMNATSHR | |
| SCHEMBL15724555 | 0.79 | MEN1 (0.60) | RAB9APOLBLMNATSHRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2840081-A1 | USE OF A NOVEL AMINOPYRIDINE DERIVATIVE TO PREVENT OR TREAT CANCER | Medicinal Bioconvergence Research Center (KR) | 2015-02-25 | — | — | EP | claimed |
| US-20150038531-A1 | USE OF A NOVEL AMINOPYRIDINE DERIVATIVE TO PREVENT OR TREAT CANCER | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2015-02-05 | — | — | US | claimed |
| US-9206132-B2 | Use of a novel aminopyridine derivative to prevent or treat cancer | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2015-12-08 | — | — | US | disclosed |
| US-9206132-B2 | Use of a novel aminopyridine derivative to prevent or treat cancer | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2015-12-08 | — | — | US | disclosed |
| US-9206132-B2 | Use of a novel aminopyridine derivative to prevent or treat cancer | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2015-12-08 | — | — | US | disclosed |
| EP-2840081-A1 | USE OF A NOVEL AMINOPYRIDINE DERIVATIVE TO PREVENT OR TREAT CANCER | Medicinal Bioconvergence Research Center (KR) | 2015-02-25 | — | — | EP | disclosed |
| CN-104379565-A | Novel aminopyridine derivatives for preventing or treating cancer | MEDICINAL BIOCONVERGENCE RES CT | 2015-02-25 | — | — | CN | disclosed |
| US-20150038531-A1 | USE OF A NOVEL AMINOPYRIDINE DERIVATIVE TO PREVENT OR TREAT CANCER | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2015-02-05 | — | — | US | disclosed |
| US-20150038531-A1 | USE OF A NOVEL AMINOPYRIDINE DERIVATIVE TO PREVENT OR TREAT CANCER | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2015-02-05 | — | — | US | disclosed |
| US-20150038531-A1 | USE OF A NOVEL AMINOPYRIDINE DERIVATIVE TO PREVENT OR TREAT CANCER | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2015-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038531-A1 | USE OF A NOVEL AMINOPYRIDINE DERIVATIVE TO PREVENT OR TREAT CANCER | DPYD, BRCA1, CYC1 | NOTUM 3701/4885RAB9A 2499/4885POLB 1527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.